Let’s talk in vivo engineered cell therapies. CAR-TCR Summit Series, Boston, Sept 17-20, 2024

Our CEO John W. Hadden II is hosting a next generation conversation not to be missed.

Sept 19 at 12:25pm “Highlighting the Next Generation Opportunity & Potential for In Vivo Engineered Cell Therapies”
with
Maurits W. Geerlings, President & Chief Executive Officer, Nanocell Therapeutics
Robert Mabry, Chief Scientific Officer, Orna Therapeutics
Ryan Crisman, Chief Technical Officer, Umoja Biopharma
Philip R. Johnson, MD, President & Chief Executive Officer, Interius BioTherapeutics

Come visit us at Booth 16. Traci Kyes John W. Hadden II

CAR-TCR Summit Series #Boston #CARTCR2024
https://ter.li/mcx1tq

#celltherapy #viralvectors #cellandgenetherapy